Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients.
Hall MS, Teer JK, Yu X, Branthoover H, Snedal S, Rodriguez-Valentin M, Nagle L, Scott E, Schachner B, Innamarato P, Hall AM, Blauvelt J, Rich CJ, Richards AD, Ceccarelli J, Langer TJ, Yoder SJ, Beatty MS, Cox CA, Messina JL, Abate-Daga D, Mule JJ, Mullinax JE, Sarnaik AA, Pilon-Thomas S. Hall MS, et al. Among authors: innamarato p. J Immunother Cancer. 2023 Oct;11(10):e007288. doi: 10.1136/jitc-2023-007288. J Immunother Cancer. 2023. PMID: 37802604 Free PMC article.
IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer.
Mandal G, Biswas S, Anadon CM, Yu X, Gatenbee CD, Prabhakaran S, Payne KK, Chaurio RA, Martin A, Innamarato P, Moran C, Powers JJ, Harro CM, Mine JA, Sprenger KB, Rigolizzo KE, Wang X, Curiel TJ, Rodriguez PC, Anderson AR, Saglam O, Conejo-Garcia JR. Mandal G, et al. Among authors: innamarato p. Cancer Res. 2022 Mar 1;82(5):859-871. doi: 10.1158/0008-5472.CAN-21-2376. Cancer Res. 2022. PMID: 34949671 Free PMC article.
Early Recovery of Myeloid-Derived Suppressor Cells After Allogeneic Hematopoietic Transplant: Comparison of Post-Transplantation Cyclophosphamide to Standard Graft-Versus-Host Disease Prophylaxis.
Oshrine B, Innamarato P, Branthoover H, Nagle L, Verdugo P, Pilon-Thomas S, Beatty M. Oshrine B, et al. Among authors: innamarato p. Transplant Cell Ther. 2022 Apr;28(4):203.e1-203.e7. doi: 10.1016/j.jtct.2021.12.019. Epub 2022 Jan 5. Transplant Cell Ther. 2022. PMID: 34995816 Free article.
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.
Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, Innamarato P, Nagle L, Branthoover H, Wiener D, Schachner B, Martinez AJ, Richards AD, Rich CJ, Colón Colón M, Schell MJ, Teer JK, Khushalani NI, Weber JS, Mulé JJ, Sondak VK, Pilon-Thomas S, Sarnaik AA. Hall MS, et al. Among authors: innamarato p. Clin Cancer Res. 2022 Dec 15;28(24):5317-5329. doi: 10.1158/1078-0432.CCR-22-2103. Clin Cancer Res. 2022. PMID: 36215121 Free PMC article. Clinical Trial.
Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites.
Martin AL, Powell C, Nagy MZ, Innamarato P, Powers J, Nichols D, Anadon CM, Chaurio RA, Kim S, Wang MH, Gong B, Wang X, Scheutz TJ, Antonia SJ, Conejo-Garcia JR, Perez BA. Martin AL, et al. Among authors: innamarato p. Cancer Immunol Immunother. 2023 Jun;72(6):1445-1460. doi: 10.1007/s00262-022-03325-y. Epub 2022 Dec 5. Cancer Immunol Immunother. 2023. PMID: 36469096 Free PMC article.
21 results